Therapeutic drug monitoring in tuberculosis
European Journal of Clinical Pharmacology · 2024
DOI: 10.1007/s00228-024-03749-8 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift European Journal of Clinical Pharmacology, 2024. Verfasst von M Sarkar und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, 171001, Himachal Pradesh, India. drsarkarmalay23@rediffmail.com. Hauptthemen laut MEDLINE: Drug Monitoring, Antitubercular Agents, Tuberculosis. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 181 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: Therapeutic drug monitoring (TDM) is a standard clinical procedure that uses the pharmacokinetic and pharmacodynamic parameters of the drug in the body to determine the optimal dose. The pharmacokinetic variability of the drug(s) is a significant contributor to poor treatment outcomes, including the development of acquired drug resistance. TDM aids in dose optimization and improves outcomes while lessening drug toxicity. TDM is used to manage patients with tuberculosis (TB) who exhibit a slow response to therapy, despite good compliance and drug-susceptible organisms. Additional indications include patients at risk of malabsorption or delayed absorption of TB drugs and patients with drug-drug interaction and drug toxicity, which confirm compliance with therapy. TDM usually requires two blood samples: the 2 h and the 6 h post-dose. This narrative review will discuss the pharmacokinetics and pharmacodynamics of TB drugs, determinants of poor response to therapy, indications of TDM, methods of performing TDM, and its interpretations. METHODS: This is a narrative review. We searched PubMed, Embase, and the CINAHL from inception to April 2024. We used the following search terms: tuberculosis, therapeutic drug monitoring, anti-TB drugs, pharmacokinetics, pharmacodynamics, limited sample strategies, diabetes and TB, HIV and TB, and multidrug-resistant TB. All types of articles were selected. RESULTS: TDM is beneficial in managing TB, especially in patients with slow responses, drug-resistance TB, recurrent TB, and comorbidities such as diabetes mellitus and human immunodeficiency virus infection. CONCLUSION: TDM is beneficial for improving outcomes, reducing the risk of acquired drug resistance, and avoiding side effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pulmonary Medicine, Indira Gandhi Medical College, Shimla, 171001, Himachal Pradesh, India. drsarkarmalay23@rediffmail.com.
- MRes Neuroscience, University of Leeds, Leeds, UK.
Zitieren
APA
Sarkar, M., & Sarkar, J. (2024). Therapeutic drug monitoring in tuberculosis. European Journal of Clinical Pharmacology. https://doi.org/10.1007/s00228-024-03749-8
Vancouver
Sarkar M, Sarkar J. Therapeutic drug monitoring in tuberculosis. European Journal of Clinical Pharmacology. 2024. doi:10.1007/s00228-024-03749-8
BibTeX
@article{Sarkar2024,
author = {Sarkar, M and Sarkar, J},
title = {Therapeutic drug monitoring in tuberculosis},
journal = {European Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1007/s00228-024-03749-8}
}
EUVIMED